Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
- The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines
- The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026
Aachen, Germany and Tokyo, Japan, 2 August 2023 – Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.
The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide.
"Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain," said Gabriel Baertschi, Chief Executive Officer, Grünenthal.
"The established medicines portfolio has a proud history of delivering life-changing value for patients. Today's announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality," said Jeremy Morgan, President, Kyowa Kirin International.
Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.
About Grünenthal Meds
As part of the Joint Venture Collaboration between Grünenthal GmbH and Kyowa Kirin Co., Ltd., a new enterprise has been created to market Kyowa Kirin International's established medicines portfolio, which comprises 13 brands across six therapeutic areas. This enterprise will be branded in all markets as Grünenthal Meds.
The portfolio includes medicines that deliver life-changing value for hundreds of thousands of patients. The portfolio is available in seven major European markets through affiliates and in various additional territories worldwide through a network of partners. Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis. Visit www.grunenthalmeds.com to find out more.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, we apply cutting-edge science, including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.
Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved sales of € 1.7 bn.
More information: www.grunenthal.com and Grünenthal Report 2022/23 digital edition (grunenthal.com)
Kyowa Kirin International
www.international.kyowa-kirin.com
Galabank Business Park
Galashiels, TD1 1QH
United Kingdom
Contacts for Kyowa Kirin International:
Media
Stacey Minton
Email: Stacey.Minton@kyowakirin.com
Contacts for Kyowa Kirin Co., Ltd.:
Media
Hiroki Nakamura
Email: media@kyowakirin.com
Grünenthal GmbH
Zieglerstr. 6
52078 Aachen
Germany
Media Contact:
Florian Dieckmann
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Xella achieves significant progress in CO₂ emissions reduction, circular economy, and occupational safety27.3.2025 11:53:22 CET | Press Release
Well positioned for sustainable growth with optimized network and enhanced processes
OpenCloud 2.0.0 offers enterprise services, support and “File Native Backup”27.3.2025 10:47:20 CET | Pressmeddelande
Berlin, Germany, March 27, 2025 – Following the successful release of OpenCloud 1.0 in February 2025, OpenCloud now launches its commercial offering including various enterprise service packages for its new solution for file management, file sharing and collaboration. OpenCloud 2.0.0 provides users with long-term software support, fast security updates, checks during update rollouts, high-availability solutions and personal support. OpenCloud can be run in in-house data centers or through selected partners. New feature for easy backup of large data volumes Version 2.0.0 also brings a new feature. “File Native Backup” makes it easy to back up data of any volume and includes a powerful full-text search. Unlike database-supported solutions, OpenCloud only requires a simple backup of the file system via a snapshot or file copy for a full, consistent backup. This means lower operating expenses, less risks of failure and process disruption, significant time saving, easier data backup and res
From historical conflicts to family ties: New8 showcases second slate of international drama series26.3.2025 15:15:28 CET | Press Release
Following the success of the first series of New8, the new projects of this international drama collaboration of eight public broadcasters were presented today at Series Mania in Lille. The partners of New8 – SVT (Sweden), DR (Denmark), YLE (Finland), RÚV (Iceland), NRK (Norway), VRT (Flanders, Belgium), NPO (Netherlands) and ZDF (Germany) – have coproduced eight drama series since the start of the collaboration in autumn 2023. The aim of New8 is to coproduce high-quality series across national borders that reflect the values of public service media and appeal to a broad audience.
Exceptional Partnership: Princess Madeleine and Weleda Launch New Skincare Brand, minLen24.3.2025 13:02:22 CET | Pressmeddelande
The first natural, responsible multi-generational skincare brand in Europe Princess Madeleine: “Weleda is the ideal partner for developing products that nurture and protect children's natural skin barrier. As a mother, I am mindful about the skincare products my family uses, making minLen a deeply personal project for me.” Weleda CEO Tina Müller: “At a time when even young children are reaching for their mother’s retinol cream, we are introducing an alternative the whole family can use without hesitation. We are honoured to have realised this important project with Madeleine.” First joint public appearance: 28 March 2025, Düsseldorf
Innovations for the Future of Retail – New Concepts and Technologies20.3.2025 10:39:31 CET | Press Release
Conzoom Solutions – Industry hub of the consumer goods fairs at Messe Frankfurt – encouraging retailers to embrace trends and actively shape the future of shopping. New technologies, innovative concepts, and the targeted emotional engagement of customers are key success factors for the retail of the future. Conzoom Solutions prepares retail for the future with up-to-date industry news, inspiration, insights, and expert contributions.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom